Kinases as targets for Parkinson's disease: From genetics to therapy

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 6, 2011, Pages 724-740

  Vancraenenbroeck, Renée ^a   Lobbestael, Evy ^a   De Maeyer, Marc ^a   Baekelandt, Veerle ^a   Taymans, Jean Marc ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alpha synuclein; Leucine rich repeat kinase 2; Polo like kinase 2

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 5 IODOTUBERCIDIN; ALPHA SYNUCLEIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; COMPOUND 4; COMPOUND 48-80; DAMNACANTHAL; ENZYME INHIBITOR; H 1152; INDIRUBIN 3' MONOOXIME; K 252A; K 252B; LDN 22684; LDN 73794; LEUCINE RICH REPEAT KINASE 2; PHOSPHOTRANSFERASE; POLO LIKE KINASE 2; SORAFENIB; STAUROSPORINE; SUNITINIB; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; BLOOD BRAIN BARRIER; DRUG BINDING; DRUG STRUCTURE; DRUG TARGETING; GENETIC LINKAGE; GENETICS; HUMAN; IC 50; INHERITANCE; NONHUMAN; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; VALIDATION STUDY;

EID: 80052828693     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711797247858     Document Type: Article

References (184)

1. Savitt, J.M.; Dawson, V.L.; Dawson, T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest., 2006, 116(7), 1744-1754.
2. Lombardino, J.G.; Lowe, J.A., 3rd. The role of the medicinal chemist in drug discovery--then and now. Nat. Rev. Drug. Discov., 2004, 3(10), 853-862.
3. Gasser, T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. Med., 2009, 11, e22.
4. Lees, A.J.; Hardy, J.; Revesz, T. Parkinson's disease. Lancet, 2009, 373(9680), 2055-2066.
5. Hardy, J.; Lewis, P.; Revesz, T.; Lees, A.; Paisan-Ruiz, C. The genetics of Parkinson's syndromes: a critical review. Curr. Opin. Genet. Dev., 2009, 19(3), 254-265.
6. Nakajima, A.; Kataoka, K.; Hong, M.; Sakaguchi, M.; Huh, N.H. BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential. Cancer Lett., 2003, 201(2), 195-201.
7. Unoki, M.; Nakamura, Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene, 2001, 20(33), 4457-4465.
8. Valente, E.M.; Abou-Sleiman, P.M.; Caputo, V.; Muqit, M.M.; Harvey, K.; Gispert, S.; Ali, Z.; Del Turco, D.; Bentivoglio, A.R.; Healy, D.G.; Albanese, A.; Nussbaum, R.; Gonzalez-Maldonado, R.; Deller, T.; Salvi, S.; Cortelli, P.; Gilks, W.P.; Latchman, D.S.; Harvey, R.J.; Dallapiccola, B.; Auburger, G.; Wood, N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 2004, 304(5674), 1158-1160.
9. Hatano, Y.; Li, Y.; Sato, K.; Asakawa, S.; Yamamura, Y.; Tomiyama, H.; Yoshino, H.; Asahina, M.; Kobayashi, S.; Hassinbaer, S.; Lu, C.S.; Ng, A.R.; Rosales, R.L.; Shimizu, N.; Toda, T.; Mizuno, Y.; Hattori, N. Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol., 2004, 56(3), 424-427.
10. Healy, D.G.; Abou-Sleiman, P.M.; Gibson, J.M.; Ross, O.A.; Jain, S.; Gandhi, S.; Gosal, D.; Muqit, M.M.; Wood, N.W.; Lynch, T. PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology, 2004, 63(8), 1486-1488.
11. Rogaeva, E.; Johnson, J.; Lang, A.E.; Gulick, C.; Gwinn-Hardy, K.; Kawarai, T.; Sato, C.; Morgan, A.; Werner, J.; Nussbaum, R.; Petit, A.; Okun, M.S.; McInerney, A.; Mandel, R.; Groen, J.L.; Fernandez, H.H.; Postuma, R.; Foote, K.D.; Salehi-Rad, S.; Liang, Y.; Reimsnider, S.; Tandon, A.; Hardy, J.; St George-Hyslop, P.; Singleton, A.B. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch. Neurol., 2004, 61(12), 1898-1904.
12. Rohe, C.F.; Montagna, P.; Breedveld, G.; Cortelli, P.; Oostra, B.A.; Bonifati, V. Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann. Neurol., 2004, 56(3), 427-431.
13. Thomas, K.J.; Cookson, M.R. The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics. Int. J. Biochem. Cell Biol., 2009, 41(10), 2025-2035.
14. Mata, I.F.; Wedemeyer, W.J.; Farrer, M.J.; Taylor, J.P.; Gallo, K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci., 2006, 29(5), 286-293.
15. Marin, I. Ancient origin of the Parkinson disease gene LRRK2. J. Mol. Evol., 2008, 67(1), 41-50.
16. Paisan-Ruiz, C.; Nath, P.; Washecka, N.; Gibbs, J.R.; Singleton, A.B. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum. Mutat., 2008, 29(4), 485-490.
17. Biskup, S.; West, A.B. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim. Biophys. Acta, 2009, 1792(7), 625-633.
18. Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M.; Kawaguchi, T.; Tsunoda, T.; Watanabe, M.; Takeda, A.; Tomiyama, H.; Nakashima, K.; Hasegawa, K.; Obata, F.; Yoshikawa, T.; Kawakami, H.; Sakoda, S.; Yamamoto, M.; Hattori, N.; Murata, M.; Nakamura, Y.; Toda, T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet., 2009, 41(12), 1303-1307.
19. Simon-Sanchez, J.; Schulte, C.; Bras, J.M.; Sharma, M.; Gibbs, J.R.; Berg, D.; Paisan-Ruiz, C.; Lichtner, P.; Scholz, S.W.; Hernandez, D.G.; Kruger, R.; Federoff, M.; Klein, C.; Goate, A.; Perlmutter, J.; Bonin, M.; Nalls, M.A.; Illig, T.; Gieger, C.; Houlden, H.; Steffens, M.; Okun, M.S.; Racette, B.A.; Cookson, M.R.; Foote, K.D.; Fernandez, H.H.; Traynor, B.J.; Schreiber, S.; Arepalli, S.; Zonozi, R.; Gwinn, K.; van der Brug, M.; Lopez, G.; Chanock, S.J.; Schatzkin, A.; Park, Y.; Hollenbeck, A.; Gao, J.; Huang, X.; Wood, N.W.; Lorenz, D.; Deuschl, G.; Chen, H.; Riess, O.; Hardy, J.A.; Singleton, A.B.; Gasser, T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet., 2009, 41(12), 1308-1312.
20. Bonifati, V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem. Res., 2007, 32(10), 1700-1708.
21. Walker, I.; Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov., 2009, 8(1), 15-16.
22. Bosgraaf, L.; Van Haastert, P.J. Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta, 2003, 1643(1-3), 5-10.
23. Marin, I. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol., 2006, 23(12), 2423-2433.
24. Marin, I.; van Egmond, W.N.; van Haastert, P.J. The Roco protein family: a functional perspective. FASEB J., 2008, 22(9), 3103-3110.
25. Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298(5600), 1912-1934.
26. Meylan, E.; Tschopp, J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci., 2005, 30(3), 151-159.
27. West, A.B.; Moore, D.J.; Biskup, S.; Bugayenko, A.; Smith, W.W.; Ross, C.A.; Dawson, V.L.; Dawson, T.M. Parkinson's diseaseassociated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA, 2005, 102(46), 16842-16847.
28. Anand, V.S.; Reichling, L.J.; Lipinski, K.; Stochaj, W.; Duan, W.; Kelleher, K.; Pungaliya, P.; Brown, E.L.; Reinhart, P.H.; Somberg, R.; Hirst, W.D.; Riddle, S.M.; Braithwaite, S.P. Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J., 2009, 276(2), 466-478.
29. Jaleel, M.; Nichols, R.J.; Deak, M.; Campbell, D.G.; Gillardon, F.; Knebel, A.; Alessi, D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J., 2007, 405(2), 307-317.
30. Nichols, R.J.; Dzamko, N.; Hutti, J.E.; Cantley, L.C.; Deak, M.; Moran, J.; Bamborough, P.; Reith, A.D.; Alessi, D.R. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J., 2009, 424(1), 47-60.
31. West, A.B.; Moore, D.J.; Choi, C.; Andrabi, S.A.; Li, X.; Dikeman, D.; Biskup, S.; Zhang, Z.; Lim, K.L.; Dawson, V.L.; Dawson, T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet., 2007, 16(2), 223-232.
32. Kumari, U.; Tan, E.K. LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J., 2009, 276(22), 6455-6463.
33. Greggio, E.; Cookson, M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neurol., 2009, 1(1).
34. Smith, W.W.; Pei, Z.; Jiang, H.; Moore, D.J.; Liang, Y.; West, A.B.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. USA, 2005, 102(51), 18676-18681.
35. Greggio, E.; Jain, S.; Kingsbury, A.; Bandopadhyay, R.; Lewis, P.; Kaganovich, A.; van der Brug, M.P.; Beilina, A.; Blackinton, J.; Thomas, K.J.; Ahmad, R.; Miller, D.W.; Kesavapany, S.; Singleton, A.; Lees, A.; Harvey, R.J.; Harvey, K.; Cookson, M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis., 2006, 23(2), 329-341.
36. Smith, W.W.; Pei, Z.; Jiang, H.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 2006, 9(10), 1231-1233.
37. MacLeod, D.; Dowman, J.; Hammond, R.; Leete, T.; Inoue, K.; Abeliovich, A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 2006, 52(4), 587-593.
38. Plowey, E.D.; Cherra, S.J., 3rd.; Liu, Y.J.; Chu, C.T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem., 2008, 105(3), 1048-1056.
39. Wang, L.; Xie, C.; Greggio, E.; Parisiadou, L.; Shim, H.; Sun, L.; Chandran, J.; Lin, X.; Lai, C.; Yang, W.J.; Moore, D.J.; Dawson, T.M.; Dawson, V.L.; Chiosis, G.; Cookson, M.R.; Cai, H. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci., 2008, 28(13), 3384-3391.
40. McKay, M.M.; Morrison, D.K. Integrating signals from RTKs to ERK/MAPK. Oncogene, 2007, 26(22), 3113-3121.
41. Marcotte, E.M.; Pellegrini, M.; Ng, H.L.; Rice, D.W.; Yeates, T.O.; Eisenberg, D. Detecting protein function and protein-protein interactions from genome sequences. Science, 1999, 285(5428), 751-753.
42. Vetter, I.R.; Wittinghofer, A. The guanine nucleotide-binding switch in three dimensions. Science, 2001, 294(5545), 1299-1304.
43. Bhattacharya, M.; Babwah, A.V.; Ferguson, S.S. Small GTP binding protein-coupled receptors. Biochem. Soc. Trans., 2004, 32(Pt 6), 1040-1044.
44. Ito, G.; Okai, T.; Fujino, G.; Takeda, K.; Ichijo, H.; Katada, T.; Iwatsubo, T. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry, 2007, 46(5), 1380-1388.
45. Liu, M.; Dobson, B.; Glicksman, M.A.; Yue, Z.; Stein, R.L. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase2: characterization of the kinase and GTPase activities. Biochemistry, 2010, 49(9), 2008-2017.
46. Lewis, P.A.; Greggio, E.; Beilina, A.; Jain, S.; Baker, A.; Cookson, M.R. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun., 2007, 357(3), 668-671.
47. Li, X.; Tan, Y.C.; Poulose, S.; Olanow, C.W.; Huang, X.Y.; Yue, Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem., 2007, 103(1), 238-247.
48. Daniëls, V.; Vancraenenbroeck, R.; Law, B.M.; Greggio, E.; Lobbestael, E.; Gao, F.; De Maeyer, M.; Cookson, M.R.; Harvey, K.; Baekelandt, V.; Taymans, J.M. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem., 2011, 116(2), 304-315.
49. Greggio, E.; Lewis, P.A.; van der Brug, M.P.; Ahmad, R.; Kaganovich, A.; Ding, J.; Beilina, A.; Baker, A.K.; Cookson, M.R. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J. Neurochem., 2007, 102(1), 93-102.
50. Deng, J.; Lewis, P.A.; Greggio, E.; Sluch, E.; Beilina, A.; Cookson, M.R. Structure of the ROC domain from the Parkinson's disease- associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. USA, 2008, 105(5), 1499-1504.
51. Greggio, E.; Zambrano, I.; Kaganovich, A.; Beilina, A.; Taymans, J.-M.; Daniels, V.; Lewis, P.; Jain, S.; Ding, J.; Syed, A.; Thomas, K.J.; Baekelandt, V.; Cookson, M.R. The Parkinson Disease- associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation. J. Biol. Chem., 2008, 283(24), 16906-16914.
52. Klein, C.L.; Rovelli, G.; Springer, W.; Schall, C.; Gasser, T.; Kahle, P.J. Homo and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J. Neurochem., 2009, 111(3), 703-715.
53. Imai, Y.; Gehrke, S.; Wang, H.Q.; Takahashi, R.; Hasegawa, K.; Oota, E.; Lu, B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J., 2008, 27(18), 2432-2443.
54. Gillardon, F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in Parkinsonian neurodegeneration? J. Neurochem., 2009, 110(5), 1514-1522.
55. Gloeckner, C.J.; Schumacher, A.; Boldt, K.; Ueffing, M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem., 2009, 109(4), 959-968.
56. Hsu, C.H.; Chan, D.; Greggio, E.; Saha, S.; Guillily, M.D.; Ferree, A.; Raghavan, K.; Shen, G.C.; Segal, L.; Ryu, H.; Cookson, M.R.; Wolozin, B. MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J. Neurochem., 2010, 112(6), 1593-1604.
57. Qing, H.; Wong, W.; McGeer, E.G.; McGeer, P.L. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun., 2009, 387(1), 149-152.
58. Kumar, A.; Greggio, E.; Beilina, A.; Kaganovich, A.; Chan, D.; Taymans, J.M.; Wolozin, B.; Cookson, M.R. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One, 2010, 5(1), e8730.
59. Parisiadou, L.; Xie, C.; Cho, H.J.; Lin, X.; Gu, X.L.; Long, C.X.; Lobbestael, E.; Baekelandt, V.; Taymans, J.M.; Sun, L.; Cai, H. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci., 2009, 29(44), 13971-13980.
60. Smith, J.A.; Francis, S.H.; Corbin, J.D. Autophosphorylation: a salient feature of protein kinases. Mol. Cell Biochem., 1993, 127-128, 51-70.
61. Nolen, B.; Taylor, S.; Ghosh, G. Regulation of protein kinases.; controlling activity through activation segment conformation. Mol. Cell, 2004, 15(5), 661-675.
62. Gloeckner, C.J.; Boldt, K.; von Zweydorf, F.; Helm, S.; Wiesent, L.; Sarioglu, H.; Ueffing, M. Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2. J. Proteome Res., 2010, 9(4), 1738-1745.
63. Kamikawaji, S.; Ito, G.; Iwatsubo, T. Identification of the autophosphorylation sites of LRRK2. Biochemistry, 2009, 48(46), 10963-10975.
64. Greggio, E.; Taymans, J.M.; Zhen, E.Y.; Ryder, J.; Vancraenenbroeck, R.; Beilina, A.; Sun, P.; Deng, J.; Jaffe, H.; Baekelandt, V.; Merchant, K.; Cookson, M.R. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun., 2009, 389(3), 449-454.
65. Taymans, J.M.; Cookson, M. Mechanisms of dominant parkinsonism.; the toxic triangle of LRRK2, alpha-synuclein and tau. Bioessays, 2010, 32(3), 227-235.
66. Gandhi, P.N.; Wang, X.; Zhu, X.; Chen, S.G.; Wilson-Delfosse, A.L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res., 2008, 86(8), 1711-1720.
67. Sancho, R.M.; Law, B.M.; Harvey, K. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum. Mol. Genet., 2009, 18(20), 3955-3968.
68. Nichols, R.J.; Dzamko, N.; Morrice, N.A.; Campbell, D.G.; Deak, M.; Ordureau, A.; Macartney, T.; Tong, Y.; Shen, J.; Prescott, A.R.; Alessi, D.R. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J., 2010, 430(3), 393-404.
69. Greengard, P. The neurobiology of dopamine signaling. Biosci. Rep., 2001, 21(3), 247-269.
70. Dzamko, N.; Deak, M.; Hentati, F.; Reith, A.D.; Prescott, A.R.; Alessi, D.R.; Nichols, R.J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J., 2010, 430(3), 405-413.
71. Deng, X.; Dzamko, N.; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J.D.; Patricelli, M.P.; Nomanbhoy, T.K.; Alessi, D.R.; Gray, N.S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol., 2011, 7(4), 203-205.
72. Gotthardt, K.; Weyand, M.; Kortholt, A.; Van Haastert, P.J.; Wittinghofer, A. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J., 2008, 27(17), 2352.
73. Dachsel, J.C.; Taylor, J.P.; Mok, S.S.; Ross, O.A.; Hinkle, K.M.; Bailey, R.M.; Hines, J.H.; Szutu, J.; Madden, B.; Petrucelli, L.; Farrer, M.J. Identification of potential protein interactors of Lrrk2. Parkinsonism Relat. Disord., 2007, 13(7), 382-385.
74. Gloeckner, C.J.; Kinkl, N.; Schumacher, A.; Braun, R.J.; O'Neill, E.; Meitinger, T.; Kolch, W.; Prokisch, H.; Ueffing, M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet., 2006, 15(2), 223-232.
75. Gasper, R.; Meyer, S.; Gotthardt, K.; Sirajuddin, M.; Wittinghofer, A. It takes two to tango: regulation of G proteins by dimerization. Nat. Rev. Mol. Cell Biol., 2009, 10(6), 423-429.
76. Pelech, S. Dimerization in protein kinase signaling. J. Biol., 2006, 5(5), 12.
77. Gallo, K.A.; Johnson, G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev., 2002, 3(9), 663-672.
78. Jorgensen, N.D.; Peng, Y.; Ho, C.C.; Rideout, H.J.; Petrey, D.; Liu, P.; Dauer, W.T. The WD40 domain is required for LRRK2 neurotoxicity. PLoS One, 2009, 4(12), e8463.
79. Sen, S.; Webber, P.J.; West, A.B. Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity: Dependence on Dimerization. J. Biol. Chem., 2009, 284(52), 36346-36356.
80. Gloeckner, C.J.; Kinkl, N.; Schumacher, A.; Braun, R.J.; O'Neill, E.; Meitinger, T.; Kolch, W.; Prokisch, H.; Ueffing, M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet., 2006, 15(2), 223-232.
81. Ding, X.; Goldberg, M.S. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One, 2009, 4(6), e5949.
82. Ko, H.S.; Bailey, R.; Smith, W.W.; Liu, Z.; Shin, J.H.; Lee, Y.I.; Zhang, Y.J.; Jiang, H.; Ross, C.A.; Moore, D.J.; Patterson, C.; Petrucelli, L.; Dawson, T.M.; Dawson, V.L. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc. Natl. Acad. Sci. USA, 2009, 106(8), 2897-2902.
83. Ohta, E.; Katayama, Y.; Kawakami, F.; Yamamoto, M.; Tajima, K.; Maekawa, T.; Iida, N.; Hattori, S.; Obata, F. I(2020)T leucinerich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule. Biochem. Biophys. Res. Commun., 2009, 390(3), 710-715.
84. Ohta, E.; Kubo, M.; Obata, F. Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis. Biochem. Biophys. Res. Commun., 2010, 391(1), 242-247.
85. Heo, H.Y.; Park, J.M.; Kim, C.H.; Han, B.S.; Kim, K.S.; Seol, W. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp. Cell Res., 2010, 316(4), 649-656.
86. Ho, C.C.; Rideout, H.J.; Ribe, E.; Troy, C.M.; Dauer, W.T. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci., 2009, 29(4), 1011-1016.
87. Daniëls, V.; Baekelandt, V.; Taymans, J.M. On the Road to Leucine-Rich Repeat Kinase 2 Signalling: Evidence from Cellular and in vivo Studies. Neurosignals, 2011, 19, 1-15.
88. Saha, S.; Guillily, M.D.; Ferree, A.; Lanceta, J.; Chan, D.; Ghosh, J.; Hsu, C.H.; Segal, L.; Raghavan, K.; Matsumoto, K.; Hisamoto, N.; Kuwahara, T.; Iwatsubo, T.; Moore, L.; Goldstein, L.; Cookson, M.; Wolozin, B. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci., 2009, 29(29), 9210-9218.
89. Wolozin, B.; Saha, S.; Guillily, M.; Ferree, A.; Riley, M. Investigating convergent actions of genes linked to familial Parkinson's disease Neurodegener. Dis., 2008, 5(3-4), 182-185.
90. Samann, J.; Hegermann, J.; von Gromoff, E.; Eimer, S.; Baumeister, R.; Schmidt, E. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J. Biol. Chem., 2009, 284(24), 16482-16491.
91. Sakaguchi-Nakashima, A.; Meir, J.Y.; Jin, Y.; Matsumoto, K.; Hisamoto, N. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol., 2007, 17(7), 592-598.
92. Shin, N.; Jeong, H.; Kwon, J.; Heo, H.Y.; Kwon, J.J.; Yun, H.J.; Kim, C.H.; Han, B.S.; Tong, Y.; Shen, J.; Hatano, T.; Hattori, N.; Kim, K.S.; Chang, S.; Seol, W. LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res., 2008, 314(10), 2055-2065.
93. Piccoli, G.; Condliffe, S.B.; Bauer, M.; Giesert, F.; Boldt, K.; De Astis, S.; Meixner, A.; Sarioglu, H.; Vogt-Weisenhorn, D.M.; Wurst, W.; Gloeckner, C.J.; Matteoli, M.; Sala, C.; Ueffing, M. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci., 2011, 31(6), 2225-2237.
94. Lee, S.B.; Kim, W.; Lee, S.; Chung, J. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem. Biophys. Res. Commun., 2007, 358(2), 534-539.
95. Lee, S.B.; Kim, W.; Lee, S.; Chung, J. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem. Biophys. Res. Commun., 2007, 358(2), 534-539.
96. Wang, D.; Tang, B.; Zhao, G.; Pan, Q.; Xia, K.; Bodmer, R.; Zhang, Z. Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol. Neurodegener., 2008, 3, 3.
97. Liu, Z.; Wang, X.; Yu, Y.; Li, X.; Wang, T.; Jiang, H.; Ren, Q.; Jiao, Y.; Sawa, A.; Moran, T.; Ross, C.A.; Montell, C.; Smith, W.W. A Drosophila model for LRRK2-linked parkinsonism. Proc. Natl. Acad. Sci. USA, 2008, 105(7), 2693-2698.
98. Ng, C.H.; Mok, S.Z.; Koh, C.; Ouyang, X.; Fivaz, M.L.; Tan, E.K.; Dawson, V.L.; Dawson, T.M.; Yu, F.; Lim, K.L. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J. Neurosci., 2009, 29(36), 11257-11262.
99. Lin, X.; Parisiadou, L.; Gu, X.L.; Wang, L.; Shim, H.; Sun, L.; Xie, C.; Long, C.X.; Yang, W.J.; Ding, J.; Chen, Z.Z.; Gallant, P.E.; Tao-Cheng, J.H.; Rudow, G.; Troncoso, J.C.; Liu, Z.; Li, Z.; Cai, H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron, 2009, 64(6), 807-827.
100. Li, Y.; Liu, W.; Oo, T.F.; Wang, L.; Tang, Y.; Jackson-Lewis, V.; Zhou, C.; Geghman, K.; Bogdanov, M.; Przedborski, S.; Beal, M.F.; Burke, R.E.; Li, C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci., 2009, 12(7), 826-828.
101. Tong, Y.; Pisani, A.; Martella, G.; Karouani, M.; Yamaguchi, H.; Pothos, E.N.; Shen, J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. USA, 2009, 106(34), 14622-14627.
102. Li, X.; Patel, J.C.; Wang, J.; Avshalumov, M.V.; Nicholson, C.; Buxbaum, J.D.; Elder, G.A.; Rice, M.E.; Yue, Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci., 2010, 30(5), 1788-1797.
103. Andres-Mateos, E.; Mejias, R.; Sasaki, M.; Li, X.; Lin, B.M.; Biskup, S.; Zhang, L.; Banerjee, R.; Thomas, B.; Yang, L.; Liu, G.; Beal, M.F.; Huso, D.L.; Dawson, T.M.; Dawson, V.L. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J. Neurosci., 2009, 29(50), 15846-15850.
104. Dusonchet, J.; Kochubey, O.; Stafa, K.; Young, S.M., Jr.; Zufferey, R.; Moore, D.J.; Schneider, B.L.; Aebischer, P. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J. Neurosci., 2011, 31(3), 907-912.
105. Lee, B.D.; Shin, J.H.; VanKampen, J.; Petrucelli, L.; West, A.B.; Ko, H.S.; Lee, Y.I.; Maguire-Zeiss, K.A.; Bowers, W.J.; Federoff, H.J.; Dawson, V.L.; Dawson, T.M. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med., 2010, 16(9), 998-1000.
106. Biskup, S.; Moore, D.J.; Celsi, F.; Higashi, S.; West, A.B.; Andrabi, S.A.; Kurkinen, K.; Yu, S.W.; Savitt, J.M.; Waldvogel, H.J.; Faull, R.L.; Emson, P.C.; Torp, R.; Ottersen, O.P.; Dawson, T.M.; Dawson, V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol., 2006, 60(5), 557-569.
107. Galter, D.; Westerlund, M.; Carmine, A.; Lindqvist, E.; Sydow, O.; Olson, L. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol., 2006, 59(4), 714-719.
108. Melrose, H.; Lincoln, S.; Tyndall, G.; Dickson, D.; Farrer, M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience, 2006, 139(3), 791-794.
109. Taymans, J.M.; Van den Haute, C.; Baekelandt, V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem., 2006, 98(3), 951-961.
110. Higashi, S.; Moore, D.J.; Colebrooke, R.E.; Biskup, S.; Dawson, V.L.; Arai, H.; Dawson, T.M.; Emson, P.C. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem., 2007, 100(2), 368-381.
111. Chen, L.; Feany, M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci., 2005, 8(5), 657-663.
112. Chen, L.; Periquet, M.; Wang, X.; Negro, A.; McLean, P.J.; Hyman, B.T.; Feany, M.B. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Invest., 2009, 119(11), 3257-3265.
113. Anderson, J.P.; Walker, D.E.; Goldstein, J.M.; de Laat, R.; Banducci, K.; Caccavello, R.J.; Barbour, R.; Huang, J.; Kling, K.; Lee, M.; Diep, L.; Keim, P.S.; Shen, X.; Chataway, T.; Schlossmacher, M.G.; Seubert, P.; Schenk, D.; Sinha, S.; Gai, W.P.; Chilcote, T.J. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem., 2006, 281(40), 29739-29752.
114. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.; Iwatsubo, T. Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol., 2002, 4(2), 160-164.
115. Hasegawa, M.; Fujiwara, H.; Nonaka, T.; Wakabayashi, K.; Takahashi, H.; Lee, V.M.-Y.; Trojanowski, J.Q.; Mann, D.; Iwatsubo, T. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem., 2002, 277(50), 49071-49076.
116. Kahle, P.J.; Neumann, M.; Ozmen, L.; Haass, C. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann. NY Acad. Sci., 2000, 920, 33-41.
117. Neumann, M.; Kahle, P.J.; Giasson, B.I.; Ozmen, L.; Borroni, E.; Spooren, W.; Maller, V.; Odoy, S.; Fujiwara, H.; Hasegawa, M.; Iwatsubo, T.; Trojanowski, J.Q.; Kretzschmar, H.A.; Haass, C. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest., 2002, 110(10), 1429-1439.
118. Takahashi, M.; Kanuka, H.; Fujiwara, H.; Koyama, A.; Hasegawa, M.; Miura, M.; Iwatsubo, T. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha- synuclein transgenic Drosophila. Neurosci. Lett., 2003, 336(3), 155-158.
119. Paleologou, K.E.; Schmid, A.W.; Rospigliosi, C.C.; Kim, H.-Y.; Lamberto, G.R.; Fredenburg, R.A.; Lansbury, P.T.; Fernandez, C.O.; Eliezer, D.; Zweckstetter, M.; Lashuel, H.A. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem., 2008, 283(24), 16895-16905.
120. Waxman, E.A.; Giasson, B.I. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol., 2008, 67(5), 402-416.
121. Azeredo da Silveira, S.; Schneider, B.L.; Cifuentes-Diaz, C.; Sage, D.; Abbas-Terki, T.; Iwatsubo, T.; Unser, M.l.; Aebischer, P. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Human Mol. Genet., 2009, 18(5), 872-887.
122. Gorbatyuk, O.S.; Li, S.; Sullivan, L.F.; Chen, W.; Kondrikova, G.; Manfredsson, F.P.; Mandel, R.J.; Muzyczka, N. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA, 2008, 105(2), 763-768.
123. McFarland, N.R.; Fan, Z.; Xu, K.; Schwarzschild, M.A.; Feany, M.B.; Hyman, B.T.; McLean, P.J. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J. Neuropathol. Exp. Neurol., 2009, 68(5), 515-24.
124. Kragh, C.L.; Lund, L.B.; Febbraro, F.; Hansen, H.D.; Gai, W.-P.; El-Agnaf, O.; Richter-Landsberg, C.; Jensen, P.H. {alpha}- Synuclein Aggregation and Ser-129 Phosphorylation-dependent Cell Death in Oligodendroglial Cells. J. Biol. Chem., 2009, 284(15), 10211-10222.
125. Luk, K.C.; Song, C.; O'Brien, P.; Stieber, A.; Branch, J.R.; Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M.-Y. Exogenous alphasynuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA, 2009, 106(47), 20051-20056.
126. Inglis, K.J.; Chereau, D.; Brigham, E.F.; Chiou, S.S.; Schobel, S.; Frigon, N.L.; Yu, M.; Caccavello, R.J.; Nelson, S.; Motter, R.; Wright, S.; Chian, D.; Santiago, P.; Soriano, F.; Ramos, C.; Powell, K.; Goldstein, J.M.; Babcock, M.; Yednock, T.; Bard, F.; Basi, G.S.; Sham, H.; Chilcote, T.J.; McConlogue, L.; Griswold-Prenner, I.; Anderson, J.P. Polo-like kinase 2 (PLK2) phosphorylates alpha- synuclein at serine 129 in central nervous system. J. Biol. Chem., 2009, 284(5), 2598-2602.
127. Schell, H.; Hasegawa, T.; Neumann, M.; Kahle, P.J. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience, 2009, 160(4), 796-804.
128. Wakamatsu, M.; Ishii, A.; Ukai, Y.; Sakagami, J.; Iwata, S.; Ono, M.; Matsumoto, K.; Nakamura, A.; Tada, N.; Kobayashi, K.; Iwatsubo, T.; Yoshimoto, M. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J. Neurosci. Res., 2007, 85(8), 1819-1825.
129. Eslamboli, A.; Romero-Ramos, M.; Burger, C.; Bjorklund, T.; Muzyczka, N.; Mandel, R.J.; Baker, H.; Ridley, R.M.; Kirik, D. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain J Neurol., 2007, 130(Pt 3), 799-815.
130. Okochi, M.; Walter, J.; Koyama, A.; Nakajo, S.; Baba, M.; Iwatsubo, T.; Meijer, L.; Kahle, P.J.; Haass, C. Constitutive phosphorylation of the Parkinson's disease associated alphasynuclein. J. Biol. Chem, 2000, 275(1), 390-397.
131. Kim, E.J.; Sung, J.Y.; Lee, H.J.; Rhim, H.; Hasegawa, M.; Iwatsubo, T.; Min, D.S.; Kim, J.; Paik, S.R.; Chung, K.C. Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J. Biol. Chem., 2006, 281(44), 33250-33257.
132. Nakamura, T.; Yamashita, H.; Takahashi, T.; Nakamura, S. Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun., 2001, 280(4), 1085-1092.
133. Negro, A.; Brunati, A.M.; Donella-Deana, A.; Massimino, M.L.; Pinna, L.A. Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J., 2002, 16(2), 210-212.
134. Mbefo, M.K.; Paleologou, K.E.; Boucharaba, A.; Oueslati, A.; Schell, H.; Fournier, M.; Olschewski, D.; Yin, G.; Zweckstetter, M.; Masliah, E.; Kahle, P.J.; Hirling, H.; Lashuel, H.A. Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem., 2010, 285(4), 2807-2822.
135. Arawaka, S.; Wada, M.; Goto, S.; Karube, H.; Sakamoto, M.; Ren, C.-H.; Koyama, S.; Nagasawa, H.; Kimura, H.; Kawanami, T.; Kurita, K.; Tajima, K.; Daimon, M.; Baba, M.; Kido, T.; Saino, S.; Goto, K.; Asao, H.; Kitanaka, C.; Takashita, E.; Hongo, S.; Nakamura, T.; Kayama, T.; Suzuki, Y.; Kobayashi, K.; Katagiri, T.; Kurokawa, K.; Kurimura, M.; Toyoshima, I.; Niizato, K.; Tsuchiya, K.; Iwatsubo, T.; Muramatsu, M.; Matsumine, H.; Kato, T. The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J. Neurosci., 2006, 26(36), 9227-9238.
136. Pronin, A.N.; Morris, A.J.; Surguchov, A.; Benovic, J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem., 2000, 275(34), 26515-26522.
137. Lee, K.W.; Chen, W.; Junn, E.; Im, J.Y.; Grosso, H.; Sonsalla, P.K.; Feng, X.; Ray, N.; Fernandez, J.R.; Chao, Y.; Masliah, E.; Voronkov, M.; Braithwaite, S.P.; Stock, J.B.; Mouradian, M.M. Enhanced Phosphatase Activity Attenuates {alpha}- Synucleinopathy in a Mouse Model. J. Neurosci., 2011, 31(19), 6963-6971.
138. Kauselmann, G.; Weiler, M.; Wulff, P.; Jessberger, S.; Konietzko, U.; Scafidi, J.; Staubli, U.; Bereiter-Hahn, J.; Strebhardt, K.; Kuhl, D. The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J., 1999, 18(20), 5528-5539.
139. Simmons, D.L.; Neel, B.G.; Stevens, R.; Evett, G.; Erikson, R.L. Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol. Cell Biol., 1992, 12(9), 4164-4169.
140. Ma, S.; Charron, J.; Erikson, R.L. Role of Plk2 (Snk) in mouse development and cell proliferation. Mol. Cell. Biol., 2003, 23(19), 6936-6943.
141. Pak, D.T.S.; Sheng, M. Targeted protein degradation and synapse remodeling by an inducible protein kinase. Science, 2003, 302(5649), 1368-1373.
142. Seeburg, D.P.; Feliu-Mojer, M.; Gaiottino, J.; Pak, D.T.S.; Sheng, M. Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron, 2008, 58(4), 571-583.
143. Lee, K.J.; Lee, Y.; Rozeboom, A.; Lee, J.Y.; Udagawa, N.; Hoe, H.S.; Pak, D.T. Requirement for Plk2 in orchestrated ras and rap signaling, homeostatic structural plasticity, and memory. Neuron, 2011, 69(5), 957-973.
144. Seeburg, D.P.; Pak, D.; Sheng, M. Polo-like kinases in the nervous system. Oncogene, 2005, 24(2), 292-298.
145. Albrecht, M. LRRK2 mutations and Parkinsonism. Lancet, 2005, 365(9466), 1230.
146. Guo, L.; Wang, W.; Chen, S.G. Leucine-rich repeat kinase 2: relevance to Parkinson's disease. Int. J. Biochem. Cell Biol., 2006, 38(9), 1469-1475.
147. Ross, O.A.; Toft, M.; Whittle, A.J.; Johnson, J.L.; Papapetropoulos, S.; Mash, D.C.; Litvan, I.; Gordon, M.F.; Wszolek, Z.K.; Farrer, M.J.; Dickson, D.W. Lrrk2 and Lewy body disease. Ann. Neurol., 2006, 59(2), 388-393.
148. Lowery, D.M.; Lim, D.; Yaffe, M.B. Structure and function of Polo-like kinases. Oncogene, 2005, 24(2), 248-259.
149. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell, 2002, 109(3), 275-282.
150. Luzon-Toro, B.; de la Torre, E.R.; Delgado, A.; Perez-Tur, J.; Hilfiker, S. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum. Mol. Genet., 2007, 16(17), 2031-2039.
151. Covy, J.P.; Giasson, B.I. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem. Biophys. Res. Commun., 2009, 378(3), 473-477.
152. Reichling, L.J.; Riddle, S.M. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochem. Biophys. Res. Commun., 2009, 384(2), 255-258.
153. Chico, L.K.; Van Eldik, L.J.; Watterson, D.M. Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discov., 2009, 8(11), 892-909.
154. Hudkins, R.L.; Diebold, J.L.; Tao, M.; Josef, K.A.; Park, C.H.; Angeles, T.S.; Aimone, L.D.; Husten, J.; Ator, M.A.; Meyer, S.L.; Holskin, B.P.; Durkin, J.T.; Fedorov, A.A.; Fedorov, E.V.; Almo, S.C.; Mathiasen, J.R.; Bozyczko-Coyne, D.; Saporito, M.S.; Scott, R.W.; Mallamo, J.P. Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl [3,4-a]pyrrolo [3,4- c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4- phenyltetrahydropyridine models. J. Med. Chem., 2008, 51(18), 5680-5689.
155. Wang, L.H.; Johnson, E.M., Jr. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology, 2008, 71(6), 462.
156. Kamenecka, T.; Jiang, R.; Song, X.; Duckett, D.; Chen, W.; Ling, Y.Y.; Habel, J.; Laughlin, J.D.; Chambers, J.; Figuera-Losada, M.; Cameron, M.D.; Lin, L.; Ruiz, C.H.; LoGrasso, P.V. Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. J. Med. Chem., 2009, 53(1), 419-431.
157. Wang, W.; Yang, Y.; Ying, C.; Li, W.; Ruan, H.; Zhu, X.; You, Y.; Han, Y.; Chen, R.; Wang, Y.; Li, M. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology, 2007, 52(8), 1678-1684.
158. Atzori, C.; Ghetti, B.; Piva, R.; Srinivasan, A.N.; Zolo, P.; Delisle, M.B.; Mirra, S.S.; Migheli, A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J. Neuropathol. Exp. Neurol., 2001, 60(12), 1190-1197.
159. Zhang, D.; Anantharam, V.; Kanthasamy, A.; Kanthasamy, A.G. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J. Pharmacol. Exp. Ther., 2007, 322(3), 913-922.
160. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C.J.; McLauchlan, H.; Klevernic, I.; Arthur, J.S.; Alessi, D.R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update. Biochem. J., 2007, 408(3), 297-315.
161. Fabian, M.A.; Biggs, W.H., 3rd.; Treiber, D.K.; Atteridge, C.E.; Azimioara, M.D.; Benedetti, M.G.; Carter, T.A.; Ciceri, P.; Edeen, P.T.; Floyd, M.; Ford, J.M.; Galvin, M.; Gerlach, J.L.; Grotzfeld, R.M.; Herrgard, S.; Insko, D.E.; Insko, M.A.; Lai, A.G.; Lelias, J.M.; Mehta, S.A.; Milanov, Z.V.; Velasco, A.M.; Wodicka, L.M.; Patel, H.K.; Zarrinkar, P.P.; Lockhart, D.J. A small molecule- kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol., 2005, 23(3), 329-336.
162. Davies, S.P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 2000, 351(Pt 1), 95-105.
163. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; Faraoni, R.; Floyd, M.; Hunt, J.P.; Lockhart, D.J.; Milanov, Z.V.; Morrison, M.J.; Pallares, G.; Patel, H.K.; Pritchard, S.; Wodicka, L.M.; Zarrinkar, P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol., 2008, 26(1), 127-132.
164. Johnson, L.N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev. Biophys., 2009, 42(1), 1-40.
165. Pardridge, W.M. Drug targeting to the brain. Pharm. Res., 2007, 24(9), 1733-1744.
166. Levin, V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem., 1980, 23(6), 682-684.
167. Patel, M.M.; Goyal, B.R.; Bhadada, S.V.; Bhatt, J.S.; Amin, A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs, 2009, 23(1), 35-58.
168. Liao, J.J.; Andrews, R.C. Targeting protein multiple conformations: a structure-based strategy for kinase drug design. Curr. Top. Med. Chem., 2007, 7(14), 1394-1407.
169. Ghose, A.K.; Herbertz, T.; Pippin, D.A.; Salvino, J.M.; Mallamo, J.P. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J. Med. Chem., 2008, 51(17), 5149-5171.
170. Sawa, M. Strategies for the design of selective protein kinase inhibitors. Mini Rev. Med. Chem., 2008, 8(12), 1291-1297.
171. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9(1), 28-39.
172. Cheng, Y.; Prusoff, W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol., 1973, 22(23), 3099-3108.
173. Knight, Z.A.; Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol., 2005, 12(6), 621-637.
174. McInnes, C.; Mezna, M.; Fischer, P.M. Progress in the discovery of polo-like kinase inhibitors. Curr. Top. Med. Chem., 2005, 5(2), 181-197.
175. Johnson, E.F.; Stewart, K.D.; Woods, K.W.; Giranda, V.L.; Luo, Y. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry, 2007, 46(33), 9551-9563.
176. Kothe, M.; Kohls, D.; Low, S.; Coli, R.; Rennie, G.R.; Feru, F.; Kuhn, C.; Ding, Y.H. Selectivity-determining residues in Plk1. Chem. Biol. Drug Des., 2007, 70(6), 540-546.
177. Cohen, M.S.; Zhang, C.; Shokat, K.M.; Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science, 2005, 308(5726), 1318-1321.
178. Lénart, P.; Petronczki, M.; Steegmaier, M.; Di Fiore, B.; Lipp, J.J.; Hoffmann, M.; Rettig, W.J.; Kraut, N.; Peters, J.M. The small- molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr. Biol., 2007, 17(4), 304-315.
179. Lansing, T.J.; McConnell, R.T.; Duckett, D.R.; Spehar, G.M.; Knick, V.B.; Hassler, D.F.; Noro, N.; Furuta, M.; Emmitte, K.A.; Gilmer, T.M.; Mook, R.A.; Cheung, M. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol. Cancer Ther., 2007, 6(2), 450-459.
180. Pagano, M.A.; Bain, J.; Kazimierczuk, Z.; Sarno, S.; Ruzzene, M.; Di Maira, G.; Elliott, M.; Orzeszko, A.; Cozza, G.; Meggio, F.; Pinna, L.A. The selectivity of inhibitors of protein kinase CK2: an update. Biochem. J., 2008, 415(3), 353-365.
181. Zhang, Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 2008, 9, 40.
182. Vulpetti, A.; Bosotti, R. Sequence and structural analysis of kinase ATP pocket residues. Farmaco, 2004, 59(10), 759-765.
183. Yun, H.; Heo, H.Y.; Kim, H.H.; Dookim, N.; Seol, W. Identification of chemicals to inhibit the kinase activity of leucine- rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein. Bioorg. Med. Chem. Lett., 2011, 21(10), 2953-2957.
184. Liu, M.; Poulose, S.; Schuman, E.; Zaitsev, A.D.; Dobson, B.; Auerbach, K.; Seyb, K.; Cuny, G.D.; Glicksman, M.A.; Stein, R.L.; Yue, Z. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors. Anal. Biochem., 2010, 404(2), 186-192.